(Q74424307)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

title

Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

author name string

Lucie Heinzerling

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Reinhard Dummer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Jovan Pavlovic

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Jan Schultz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Günter Burg

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

Karin Moelling

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

publication date

1 June 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

published in

Experimental Dermatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

page(s)

232-240

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

10 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Potential uses of interferon alpha 2 as adjuvant therapy in cancer

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Biologic therapy of melanoma with cytokines and lymphocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Peritumoral injections of interleukin 2 induce tumour regression in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Role of Interferons in the Thearpy of Melanoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Phase I study of intratumoral application of recombinant human tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Cytokine gene therapy or infusion as treatment for solid human cancer.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Induction of long-lasting cytokine effect by injection of IL-12 encoding plasmid DNA

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: implications for a clinically relevant tumor vaccine

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Long-lasting anti-metastatic efficiency of interleukin 12-encoding plasmid DNA.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

DNA-based immunization by in vivo transfection of dendritic cells

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

DNA vaccination: transfection and activation of dendritic cells as key events for immunity

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Interleukin-12-secreting fibroblasts are more efficient than free recombinant interleukin-12 in inducing the persistent resistance to Mycobacterium avium complex infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

A Role for the Interferon-Inducible Protein 10 in Inhibition of Angiogenesis by Interleukin-12

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

IL-12 regulates VEGF and MMPs in a murine breast cancer model

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0625.2001.110306.X

7 January 2021

10.1034/J.1600-0625.2001.110306.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12102662%20AND%20SRC:MED&resulttype=core&format=json

10 November 2019

1 reference